Pathos’ $365M series D to support clinical prostate cancer program: Finance Report

Less than seven months after Pathos AI closed a $62 million series C round, an undisclosed investor group has backed the Chicago-based start-up with a $365 million series D that will support clinical testing of its prostate cancer therapy.

Pathos AI Inc. has already begun dosing patients with metastatic, castration-resistant disease in a Phase Ib/IIa study of pocenbrodib, a CBP/p300 inhibitor. The company is using its AI platform to select patients likely to benefit from the therapy, using predictive biomarkers...